TAPI Technology & API Services and Sagimet Biosciences Inc. today announced entry into a license agreement.
The announcement reflects a collaboration between TAPI, a global leader in the development and manufacturing of active pharmaceutical ingredients, and Sagimet Biosciences, a clinical-stage biopharmaceutical company focused on developing novel therapeutics. This collaboration brings together complementary expertise and capabilities from both organizations.
Dr. R. Ananthanarayanan, CEO of TAPI, said:
“We are excited to announce the license agreement with Sagimet for their FDC development program, contributing TAPI’s deep experience in the development and manufacturing of APIs. APIs are essential components used in the production of medications, and TAPI has long been recognized as an industry leader in their development and manufacturing. With this collaboration with Sagimet, we are excited to contribute our innovative intellectual property and manufacturing know-how to Sagimet’s development of a product in an area of high medical need, cirrhosis of the liver, where there are currently no approved therapies.”
Further details regarding the agreement and the collaboration are provided in the full press release.
Read the full press release here: [Link]
DCAT 2026
